GlassScriptPhysician profile
Pankaj P Ram
NPI 1679539837
$9,325.54
in general payments reported to CMS, 2019-2025
28 companies · $53.04 in 2025
The $53.04 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,929 · 2020: $235 · 2021: $440 · 2022: $371 · 2023: $913 · 2024: $385 · 2025: $53.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,334 · Education: $16.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,333.81 |
| Education | $16.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $6,529.23 | 2019-2024 | Farxiga, Lokelma |
| Amgen INC. | $462.20 | 2019-2024 | Aranesp, Parsabiv, Tavneos |
| Fresenius USA Marketing, INC. | $433.82 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $347.26 | 2019-2024 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $212.53 | 2021-2024 | |
| Mallinckrodt Hospital Products INC. | $187.87 | 2020-2024 | Acthar |
| Horizon Therapeutics Plc | $154.29 | 2022-2023 | Krystexxa |
| Baxter Healthcare | $124.74 | 2019 | |
| Calliditas Therapeutics US INC. | $89.55 | 2022-2023 | Tarpeyo |
| Travere Therapeutics, INC. | $88.83 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $65.11 | 2024-2025 | |
| Daiichi Sankyo INC. | $61.66 | 2019-2023 | Injectafer |
| Octapharma USA, INC. | $58.03 | 2019 | |
| Glaxosmithkline, LLC. | $51.79 | 2022-2023 | Benlysta |
| Genzyme Corporation | $43.44 | 2023-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $43.44 | 2019 | |
| Aurinia Pharma U.S., INC. | $42.70 | 2023-2024 | Lupkynis |
| Akebia Therapeutics INC | $42.38 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $35.87 | 2019 | |
| Ani Pharmaceuticals, INC. | $35.57 | 2024 | Purified Cortrophin Gel |
| Amicus Therapeutics, INC. | $34.28 | 2019-2022 | |
| Vifor Pharma, INC. | $34.00 | 2019-2022 | |
| Scpharmaceuticals INC. | $33.93 | 2024 | |
| Opko Pharmaceuticals, LLC | $29.65 | 2020-2023 | Rayaldee |
| Mallinckrodt Enterprises LLC | $22.35 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $22.27 | 2022 | |
| Novo Nordisk INC | $21.67 | 2025 | Ozempic |
| Kyowa Kirin, INC. | $17.08 | 2023 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pankaj Ram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.